Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

NCT01005901 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01005901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01005901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-week Treatment, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2009
Completion date
December 31, 2010
Enrollment
1,324 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease